Cryoport Inc

Aptorum Group Limited is a clinical stage biopharmaceutical company based in New York, NY. They are dedicated to discovering, developing, and commercializing therapeutic assets to treat diseases with unmet medical needs, particularly in oncology and infectious diseases. Their pipeline includes drug discovery platforms and a novel molecular-based rapid pathogen identification and detection diagnostics technology. Aptorum Group is focused on facilitating the development of medical innovations that can significantly improve clinical and surgical experiences and meet current unmet medical needs. With a deep portfolio and strong life science development capabilities, they are driven by the enthralling market potential and growth prospects in the field of healthcare. Their mission is to tackle unmet medical needs and make a positive impact on patients' lives.Generated from the website

Absci Ai Research Lab is a generative AI drug creation company based in New York, NY. They are dedicated to creating better biologics for patients at a faster pace by designing antibodies from scratch using their zero-shot AI approach. Their breakthrough technology combines AI with synthetic biology to overcome the limitations of traditional drug discovery, enabling them to build and test millions of AI designs every week and validate new biologic-based therapeutics in as little as six weeks. Absci's innovative platform has the potential to disrupt the biopharmaceutical industry, with collaborations and partnerships with leading companies such as Merck, AstraZeneca, EQRx, and Almirall. Their powerful data generation and AI protein engineering platform, coupled with their unique disease biology insights, is revolutionizing drug discovery and production, offering innovative and cost-effective treatment options for patients.Generated from the website

Xalud Therapeutics is a clinical-stage biotechnology company based in New York, NY, that is dedicated to developing a non-viral plasmid DNA-delivered gene therapy platform to treat chronic inflammatory diseases by restoring balance in the immune system. Their lead candidate, XT-150, is a locally injectable gene therapy that expresses a modified version of interleukin-10 (IL-10v), a potent cytokine that regulates multiple inflammatory pathways. Xalud aims to transform the treatment of chronic inflammatory diseases by addressing the underlying cause of the disease and improving the lives of patients burdened by these conditions.Generated from the website